[Can serum protein S100beta predict neurological deterioration after moderate or minor traumatic brain injury?]
| Autor: | Bouzat, Pierre, Francony, Gilles, Declety, Philippe, Brun, Julien, Kaddour, Affif, Renversez, Jean-Charles, Jacquot, Claude, Payen, Jean-François |
|---|---|
| Přispěvatelé: | Neuro-imagerie fonctionnelle et métabolique (ANTE-INSERM U836, équipe 5), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle anesthésie-réanimation (Grenoble), CHU Grenoble-Hôpital Michallon, Service des urgences chirurgicales, Département de biologie intégrée, Dojat, Michel |
| Jazyk: | francouzština |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male MESH: Trauma Severity Indices Adolescent S100 Calcium Binding Protein beta Subunit Young Adult MESH: Aged 80 and over Predictive Value of Tests Aggravation neurologique MESH: Glasgow Coma Scale Humans Glasgow Coma Scale [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] Nerve Growth Factors Protéine S-100 Aged Aged 80 and over MESH: Adolescent MESH: Aged Trauma Severity Indices MESH: Humans MESH: Middle Aged Multiple Trauma MESH: Nerve Growth Factors S100 Proteins MESH: Multiple Trauma MESH: Confounding Factors (Epidemiology) MESH: Biological Markers Confounding Factors Epidemiologic MESH: Adult Traumatisme crânien Middle Aged MESH: Male MESH: Predictive Value of Tests MESH: Young Adult Brain Injuries MESH: Brain Injuries Disease Progression Female MESH: Disease Progression [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] MESH: S100 Proteins MESH: Female Biomarkers |
| Zdroj: | Annales Françaises d'Anesthésie et de Réanimation Annales Françaises d'Anesthésie et de Réanimation, Elsevier Masson, 2009, 28 (2), pp.135-9. ⟨10.1016/j.annfar.2008.12.019⟩ |
| ISSN: | 0750-7658 |
| DOI: | 10.1016/j.annfar.2008.12.019⟩ |
| Popis: | International audience; INTRODUCTION: Patients with moderate traumatic brain injury (TBI) (Glasgow Coma Scale, GCS, 9-13) or minor TBI (GCS 14-15) are at risk for subsequent neurological deterioration. Serum protein S-100 is believed to reflect brain damage following TBI. In patients with normal or minor CT scan abnormalities on admission, we tested whether the determination of serum protein S-100 beta could predict secondary neurological deterioration. METHODS: Sixty-seven patients with moderate or minor TBI were prospectively studied. Serum samples were collected on admission within 12 hours postinjury to measure serum protein S-100 levels. Neurological outcome was assessed up to seven days after trauma. Secondary neurological deterioration was defined as two points or more decrease from the initial GCS, or any treatment for neurological deterioration. RESULTS: Nine patients had a secondary neurological deterioration after trauma. No differences in serum levels of protein S-100 were found between these patients and those without neurological aggravation (n=58 patients): 0.93 microg/l (0.14-4.85) vs 0.39 microg/l (0.04-6.40), respectively. The proportion of patients with abnormal levels of serum protein S-100 at admission according to two admitted cut-off levels (>0.1 and >0.5 microg/l) was comparable between the two groups of patients. Elevated serum levels of protein S-100 were found in patients with Injury Severity Score (ISS) of more than 16 (n=23 patients): 1.26 microg/l (0.14-6.40) vs 0.22 microg/l (0.04-6.20) in patients with ISS less than 16 (n=44 patients). DISCUSSION: The dosage of serum protein S-100 on admission failed to predict patients at risk for neurological deterioration after minor or moderate TBI. Extracranial injuries can increase serum protein S-100 levels, then limiting the usefulness of this dosage in this clinical setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect